'HK must leverage its strengths for biopharma goals'
Health chief Lo Chung-mau said Hong Kong must play to its strengths and support the country's biopharmaceutical innovation and application. Speaking on RTHK's "Vision 15: Hong Kong's Chapter", Lo said the SAR has clear advantages – high‑quality healthcare, a well‑standardised public hospital system and two world‑class medical schools, with a third on the way. He said these are essential for…
Health chief Lo Chung-mau urged Hong Kong to capitalize on its strengths to boost the country's biopharmaceutical innovation and application. Addressing RTHK's Vision 15: Hong Kong's Chapter, Lo highlighted the city's notable advantages, including its high-quality healthcare, standardized public hospital system, and world-class medical schools, with a third under construction. These factors are crucial for medical innovation and place Hong Kong in a robust position to support the nation's biopharmaceutical goals.
Lo acknowledged that biopharmaceutical research requires clinical trials and sufficient cases, which Hong Kong currently lacks. He suggested that the Greater Bay Area and the entire country could provide the necessary cases. Furthermore, Lo emphasized that biopharmaceuticals also necessitate a market, another benefit the Greater Bay Area and the nation offer collectively.
The government places significant importance on biopharmaceuticals. Currently, mainland biopharmaceutical companies rank second globally in innovative drug development. Lo stressed that Hong Kong must utilize its strengths and collaborate with the country's biopharmaceutical innovation efforts.
Written by urgent.news from RTHK News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- 'HK must leverage its strengths for biopharma goals' news.rthk.hk
